Symbols / MBIO Stock $0.75 -0.66% Mustang Bio, Inc.

Healthcare • Biotechnology • United States • NCM
MBIO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Manuel Litchman M.D.
Exch · Country NCM · United States
Market Cap 5.68M
Enterprise Value -11.59M
Income -1.92M
Sales —
FCF (ttm) -4.15M
Book/sh 1.31
Cash/sh 2.28
Employees 4
Insider 10d —
IPO Aug 22, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.14
PEG —
P/S —
P/B 0.57
P/C —
EV/EBITDA 4.83
EV/Sales —
Quick Ratio 2.21
Current Ratio 2.22
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.39
EPS next Y -0.35
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-03-28
Earnings (prior) 2025-03-28
ROA -11.30%
ROE -67.93%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 6.73M
Shs Float 5.35M
Insider Own 4.30%
Instit Own 10.10%
Short Float 1.50%
Short Ratio 2.77
Short Interest 101.08K
52W High 7.00
vs 52W High -89.30%
52W Low 0.53
vs 52W Low 41.05%
Beta 2.18
Impl. Vol. —
Rel Volume 0.27
Avg Volume 167.22K
Volume 45.63K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.75
Price $0.75
Change -0.66%
About

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.75
Latest analyst target
3. DCF / Fair value
$-11.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.75
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-05-16 reit HC Wainwright & Co. Buy → Buy $2
2024-05-13 main HC Wainwright & Co. Buy → Buy $2
2023-08-24 reit Cantor Fitzgerald Overweight → Overweight $18
2023-08-16 reit HC Wainwright & Co. Buy → Buy $25
2023-08-15 main BTIG Buy → Buy $16
2023-08-15 reit HC Wainwright & Co. Buy → Buy $25
2023-06-16 main BTIG — → Buy $20
2023-06-16 reit HC Wainwright & Co. Buy → Buy $25
2023-05-15 reit HC Wainwright & Co. Buy → Buy $7
News
RSS: Latest MBIO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-02 FORTRESS BIOTECH, INC. Beneficial Owner of more than 10% of a Class of Security — 278,385 $0.00 $0
2025-12-30 HERSKOWITZ NEIL Director — 247 $0.96 $238
2025-12-30 CHILL ADAM J Director — 4 $0.95 $4
2025-12-30 JIN DAVID Director — 247 $0.96 $238
2025-09-29 FORTRESS BIOTECH, INC. Beneficial Owner of more than 10% of a Class of Security — 59,334 $0.00 $0
2025-03-31 FORTRESS BIOTECH, INC. Beneficial Owner of more than 10% of a Class of Security — 67,806 $0.00 $0
2024-06-27 FORTRESS BIOTECH, INC. Beneficial Owner of more than 10% of a Class of Security — 575,191 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
2.43
-80.63%
12.55
-75.25%
50.73
-33.39%
76.16
Research And Development
-1.52
-118.01%
8.42
-79.49%
41.04
-35.82%
63.95
Selling General And Administration
3.95
-4.52%
4.13
-57.31%
9.69
-20.67%
12.21
General And Administrative Expense
3.95
-4.52%
4.13
-57.31%
9.69
-20.67%
12.21
Other Gand A
3.95
-4.52%
4.13
-57.31%
9.69
-20.67%
12.21
Other Operating Expenses
—
—
—
-1.30
Total Expenses
2.43
-80.63%
12.55
-75.25%
50.73
-33.39%
76.16
Operating Income
-2.43
+80.63%
-12.55
+75.25%
-50.73
+33.39%
-76.16
Total Operating Income As Reported
-2.43
+85.03%
-16.25
+67.02%
-49.26
+35.32%
-76.16
EBITDA
-2.39
+79.62%
-11.73
+75.60%
-48.06
+32.43%
-71.14
Normalized EBITDA
-2.39
+70.25%
-8.04
+82.80%
-46.73
+34.30%
-71.14
Reconciled Depreciation
0.04
-95.02%
0.82
-63.01%
2.23
-26.59%
3.03
EBIT
-2.43
+80.63%
-12.55
+75.04%
-50.29
+32.19%
-74.17
Total Unusual Items
0.00
+100.00%
-3.69
-177.59%
-1.33
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-3.69
-177.59%
-1.33
0.00
Special Income Charges
0.00
+100.00%
-3.69
-177.59%
-1.33
0.00
Other Special Charges
—
—
2.80
—
Impairment Of Capital Assets
0.00
-100.00%
3.69
0.00
—
Write Off
—
3.69
0.00
—
Net Income
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Pretax Income
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Net Non Operating Interest Income Expense
0.51
+185.47%
0.18
+138.66%
-0.46
+82.66%
-2.67
Interest Expense Non Operating
—
0.01
-99.62%
1.31
-60.91%
3.36
Net Interest Income
0.51
+185.47%
0.18
+138.66%
-0.46
+82.66%
-2.67
Interest Expense
—
0.01
-99.62%
1.31
-60.91%
3.36
Interest Income Non Operating
0.51
+185.47%
0.18
-78.94%
0.85
+23.37%
0.69
Interest Income
0.51
+185.47%
0.18
-78.94%
0.85
+23.37%
0.69
Other Income Expense
—
-3.38
-717.92%
-0.41
-131.67%
1.30
Other Non Operating Income Expenses
—
0.31
-65.76%
0.92
-29.68%
1.30
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Net Income From Continuing Operation Net Minority Interest
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Net Income From Continuing And Discontinued Operation
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Net Income Continuous Operations
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Normalized Income
-1.92
+84.07%
-12.06
+76.01%
-50.27
+35.15%
-77.53
Net Income Common Stockholders
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Diluted EPS
-0.39
+98.99%
-38.57
+87.14%
-299.95
+46.68%
-562.50
Basic EPS
-0.39
+98.99%
-38.57
+87.14%
-299.95
+46.68%
-562.50
Basic Average Shares
4.91
+705.02%
0.61
+254.41%
0.17
+24.74%
0.14
Diluted Average Shares
4.91
+705.02%
0.61
+254.41%
0.17
+24.74%
0.14
Diluted NI Availto Com Stockholders
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Gain On Sale Of PPE
—
0.00
-100.00%
1.47
0.00
Line Item Trend 2023-12-31
Total Assets
17.74
Current Assets
11.35
Cash Cash Equivalents And Short Term Investments
6.23
Cash And Cash Equivalents
6.23
Receivables
3.88
Other Receivables
3.88
Prepaid Assets
—
Assets Held For Sale Current
0.00
Other Current Assets
1.23
Total Non Current Assets
6.40
Net PPE
4.81
Gross PPE
9.29
Accumulated Depreciation
-4.48
Properties
0.00
Machinery Furniture Equipment
0.00
Construction In Progress
0.03
Other Properties
1.57
Leases
7.69
Other Non Current Assets
1.58
Total Liabilities Net Minority Interest
17.62
Current Liabilities
15.37
Payables And Accrued Expenses
12.01
Payables
7.16
Accounts Payable
6.32
Current Accrued Expenses
4.86
Pensionand Other Post Retirement Benefit Plans Current
2.84
Current Debt And Capital Lease Obligation
0.52
Current Capital Lease Obligation
0.52
Total Non Current Liabilities Net Minority Interest
2.25
Long Term Debt And Capital Lease Obligation
1.98
Long Term Debt
—
Long Term Capital Lease Obligation
1.98
Non Current Deferred Liabilities
0.27
Non Current Deferred Revenue
0.27
Stockholders Equity
0.12
Common Stock Equity
0.12
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
1.01
Ordinary Shares Number
1.01
Treasury Shares Number
0.00
Additional Paid In Capital
380.50
Retained Earnings
-380.97
Total Equity Gross Minority Interest
0.12
Total Capitalization
0.12
Working Capital
-4.03
Invested Capital
0.12
Total Debt
2.50
Capital Lease Obligations
2.50
Net Tangible Assets
0.12
Tangible Book Value
0.12
Duefrom Related Parties Current
0.00
Dueto Related Parties Current
0.83
Other Equity Interest
0.59
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.26
+53.87%
-11.41
+76.94%
-49.48
+23.96%
-65.07
Cash Flow From Continuing Operating Activities
-5.26
+53.87%
-11.41
+76.94%
-49.48
+23.96%
-65.07
Net Income From Continuing Operations
-1.92
+87.80%
-15.75
+69.47%
-51.60
+33.44%
-77.53
Depreciation Amortization Depletion
0.04
-95.02%
0.82
-63.01%
2.23
-26.59%
3.03
Depreciation
0.04
-95.02%
0.82
-63.01%
2.23
-26.59%
3.03
Depreciation And Amortization
0.04
-95.02%
0.82
-63.01%
2.23
-26.59%
3.03
Other Non Cash Items
-1.83
-21.43%
-1.51
-254.09%
0.98
-65.80%
2.86
Stock Based Compensation
0.13
+128.67%
-0.45
-179.23%
0.57
-75.12%
2.28
Asset Impairment Charge
0.00
-100.00%
3.69
0.00
—
Operating Gains Losses
—
0.03
-97.82%
1.33
+421.57%
0.26
Gain Loss On Sale Of PPE
0.00
-100.00%
0.03
+101.98%
-1.47
-674.90%
0.26
Change In Working Capital
-1.68
-195.90%
1.75
+158.97%
-2.98
-173.85%
4.03
Change In Receivables
0.43
-11.94%
0.49
+113.80%
-3.58
-357900.00%
-0.00
Change In Prepaid Assets
0.09
-84.64%
0.59
-46.34%
1.09
+208.55%
-1.01
Change In Payables And Accrued Expense
-2.13
-271.90%
1.24
+546.88%
0.19
-96.38%
5.30
Change In Payable
—
—
0.19
-96.38%
5.30
Change In Account Payable
—
—
0.19
-96.38%
5.30
Change In Other Working Capital
—
-0.12
—
—
Change In Other Current Liabilities
-0.07
+83.67%
-0.45
+34.26%
-0.68
-158.56%
-0.26
Investing Cash Flow
1.17
0.00
-100.00%
5.89
+299.39%
-2.95
Cash Flow From Continuing Investing Activities
1.17
0.00
-100.00%
5.89
+299.39%
-2.95
Net PPE Purchase And Sale
1.17
0.00
-100.00%
5.94
+329.45%
-2.59
Purchase Of PPE
—
0.00
+100.00%
-0.06
+97.64%
-2.71
Sale Of PPE
1.17
0.00
-100.00%
6.00
+4624.41%
0.13
Capital Expenditure
—
—
-0.11
+96.30%
-3.08
Net Intangibles Purchase And Sale
—
0.00
+100.00%
-0.05
+86.30%
-0.36
Purchase Of Intangibles
—
0.00
+100.00%
-0.05
+86.30%
-0.36
Financing Cash Flow
14.53
+28.95%
11.27
+143.19%
-26.08
-176.58%
34.06
Cash Flow From Continuing Financing Activities
14.53
+28.95%
11.27
+143.19%
-26.08
-176.59%
34.06
Net Issuance Payments Of Debt
—
0.00
+100.00%
-30.38
-201.25%
30.00
Issuance Of Debt
—
—
0.00
-100.00%
30.00
Repayment Of Debt
—
0.00
+100.00%
-30.38
0.00
Long Term Debt Issuance
—
—
0.00
-100.00%
30.00
Long Term Debt Payments
—
—
-30.38
0.00
Net Long Term Debt Issuance
—
—
-30.38
-201.25%
30.00
Short Term Debt Payments
—
0.00
+100.00%
-30.38
—
Net Short Term Debt Issuance
—
0.00
+100.00%
-30.38
—
Net Common Stock Issuance
7.38
-4.07%
7.69
+68.69%
4.56
-31.13%
6.62
Proceeds From Stock Option Exercised
7.14
+100.08%
3.57
+1906.18%
0.18
-13.59%
0.21
Net Other Financing Charges
—
-1.46
-226.97%
-0.45
+83.95%
-2.77
Changes In Cash
10.43
+7291.03%
-0.14
+99.79%
-69.67
-105.15%
-33.96
Beginning Cash Position
6.84
-2.08%
6.98
-90.89%
76.66
-30.70%
110.62
End Cash Position
17.27
+152.46%
6.84
-2.08%
6.98
-90.89%
76.66
Free Cash Flow
-5.26
+53.87%
-11.41
+76.99%
-49.59
+27.23%
-68.14
Interest Paid Supplemental Data
—
0.00
-100.00%
1.34
-50.55%
2.71
Common Stock Issuance
7.38
-4.07%
7.69
+68.69%
4.56
-31.13%
6.62
Issuance Of Capital Stock
7.38
-4.07%
7.69
+68.69%
4.56
-31.13%
6.62
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category